MPO, myeloperoxidase

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis
Bernhard Hellmich, Oliver Flossmann, Wolfgang L Gross, Paul Bacon, Jan Willem Cohen-Tervaert, Loic Guillevin, David Jayne, Alfred Mahr, Peter A Merkel, Heiner Raspe, David G I Scott, James Witter, Hasan Yazici, Raashid A Luqmani

Annals of the Rheumatic Diseases May 2007, 66 (5) 605-617; DOI: 10.1136/ard.2006.062711
Clinical interpretation of antineutrophil cytoplasmic antibodies: parvovirus B19 infection as a pitfall
J Hermann, U Demel, D Stünzner, E Daghofer, G Tilz, W Graninger

Annals of the Rheumatic Diseases Apr 2005, 64 (4) 641-643; DOI: 10.1136/ard.2004.024877
Chimeric antibodies to proteinase 3 of IgG1 and IgG3 subclasses induce different magnitudes of functional responses in neutrophils
Rachel Colman, Abdullah Hussain, Margaret Goodall, Steven P Young, Tanya Pankhurst, Xiaomei Lu, Royston Jefferis, Caroline O S Savage, Julie M Williams

Annals of the Rheumatic Diseases May 2007, 66 (5) 676-682; DOI: 10.1136/ard.2006.061374
Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies
Richard Watts, Suzanne Lane, Thomas Hanslik, Thomas Hauser, Bernhard Hellmich, Wenche Koldingsnes, Alfred Mahr, Mårten Segelmark, Jan W Cohen-Tervaert, David Scott

Annals of the Rheumatic Diseases Feb 2007, 66 (2) 222-227; DOI: 10.1136/ard.2006.054593

Log in using your username and password

Main menu

Log in using your username and password

You are here

MPO, myeloperoxidase